CoChat
Sign Up
Cited by 11Heart Failure Treatment and ManagementCardiomyopathy and Myosin StudiesDiabetes Treatment and Management

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy

Fath, Ayman R., Aglan, Amro, Maron, Martin S., Phillips, Jason S., Maron, Barry J., Rowin, Ethan J.·2025·International Journal of Cardiology
DOI 10.1016/j.ijcard.2025.133082
Open this paper in CoChat — free account

Abstract

BACKGROUND Obesity is highly prevalent in patients with hypertrophic cardiomyopathy (HCM) and associated with a more severe phenotype and worse outcomes. Glucagon-like peptide-1 (GLP-1) receptor agonists have recently been shown to improve cardiovascular outcomes in patients with obesity. However, their impact on patients with obesity and HCM is unclear. Therefore we sought to assess the safety and efficacy of GLP-1 agonists in patients with obesity and HCM. METHODS Using the TriNetX Global Research Network, patients with HCM and BMI ≥30 kg/m2 were identified from 2016 to 2024 and classified into those who received GLP-1 agonists and those who did not. Groups were propensity matched to control for baseline confounders and evaluated for outcomes including all-cause mortality, heart failure hospitalization and arrhythmias. RESULTS Of 29,521 patients with HCM, 1553 (5 %) received GLP-1 agonists. After propensity score matching, both groups (n = 1497 in each) had comparable baseline characteristics. Over a 2-year follow-up period, patients with HCM on GLP-1 agonists had a significant reduction in BMI and lower all-cause mortality and HF hospitalization rates compared to patients not on GLP-1 agonists. In contrast, there was no significant differences in new-onset atrial fibrillation or ventricular arrhythmia, nor was there a significant difference in safety events related to GLP-agonist use. CONCLUSION In this large real-world dataset, the use of GLP-1 agonists in patients with obesity and HCM was associated with improved survival and lower rates of HF hospitalization. These data support future large prospective clinical trials of GLP-1 agonists in patients with obesity and HCM.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijcard.2025.133082

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Fath, A. R., Aglan, A., Maron, M. S., Phillips, J. S., Maron, B. J., & Rowin, E. J.
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • Westchester Medical Center (US)
  • Lahey Hospital and Medical Center (US)
Corresponding author
Rowin, Ethan J.
ORCID
Venue
International Journal of Cardiology
Publisher
Elsevier BV
Published
2025-05
Volume
426
Pages
133082
ISSN
0167-5273 (ISSN-L)
DOI
10.1016/j.ijcard.2025.133082
OpenAlex
W4407723245
Semantic Scholar
1f1a876cd3bd6eb87752db1c4d71b444af0cffad
Cited by
11
References
8
Citations by year
2026: 9 · 2025: 2
FWCI
6.81
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Journal of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, hypertrophic cardiomyopathy, obesity, cardiovascular outcomes, all-cause mortality, heart failure hospitalization, atrial fibrillation, ventricular arrhythmias, body mass index reduction, drug safety
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Cardiomyopathy, Hypertrophic, Female, Follow-Up Studies, Hospitalization, Humans, Male, Middle Aged, Obesity, Retrospective Studies, Treatment Outcome, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review